Recombinant toxic shock syndrome toxin-1 variant vaccine - Biomedizinische Forschungsgesellschaft

Drug Profile

Recombinant toxic shock syndrome toxin-1 variant vaccine - Biomedizinische Forschungsgesellschaft

Alternative Names: BioMed rTSST-1 variant vaccine - Biomedizinische Forschungsgesellschaft; ORG 28077; rTSST-1 variant vaccine - Biomedizinische Forschungsgesellschaft

Latest Information Update: 28 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biomedizinische Forschungsgesellschaft
  • Class Bacterial vaccines; Protein-vaccines; Recombinant proteins; Synthetic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Bacterial infections

Most Recent Events

  • 01 May 2016 Biomedizinische Forschungsgesellschaft completes a phase I trial for Bacterial infections (Prevention) in Austria (NCT02971670)
  • 29 Mar 2016 Phase-II clinical trials in Bacterial infections (Prevention) in Austria (IM)
  • 22 Jul 2015 Biomedizinische Forschungsgesellschaft completes a phase I trial in Staphylococcal infections in Austria (NCT02340338)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top